Failure of bevacizumab in early-stage colon cancer

Daniel Sargent

A randomised phase III trial of patients with stage II and III colon cancer showed no benefit of adding bevacizumab to standard adjuvant oxaliplatin plus fluorouracil and leucovorin. Despite suggestive evidence of a short-term benefit, these data and other similar findings dictate that adjuvant bevacizumab should not be used in colon cancer.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.


*


UA-77507851-1